Moreover, validation of the efficacy of hUCB-MSC-secreted GAL-3 in tauopathy animal models, such as Tau P301S Tg mice, will further demonstrate its applicability as a therapeutic agent for neurodegenerative diseases associated with tauopathy. This evidence concerns the gene LGALS3 and tauopathy.